Résultats de la recherche
10
Tout
Rechercher les filtres
Organisation
OXB
OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category
21 mars 2025 08h00 HE
|
OXB
OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category Oxford, UK – 21 March 2025: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene...
OXB to present at the Leerink Partners Global Healthcare Conference
26 févr. 2025 07h00 HE
|
OXB
OXB to present at the Leerink Partners Global Healthcare Conference Oxford, UK – 26 February 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces...
OXB’s lentiviral vector manufacturing technology to support Boehringer Ingelheim’s newly initiated Phase I/II trial of first-in-class gene therapy for cystic fibrosis
20 févr. 2025 08h36 HE
|
OXB
OXB’s lentiviral vector manufacturing technology to support Boehringer Ingelheim’s newly initiated Phase I/II trial of first-in-class gene therapy for cystic fibrosis Commencement of LENTICLAIR™ 1...
Appointment of Joint Corporate Broker and Joint Financial Adviser
05 févr. 2025 07h00 HE
|
OXB
Oxford, UK – 5 February 2025: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Jefferies International Limited ("Jefferies") as its Joint...
OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical development
20 nov. 2024 07h00 HE
|
OXB
OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical development Oxford, UK – 20 November 2024: OXB (LSE: OXB), a quality and...
Interim Results for the Six Months Ended 30 June 2024
23 sept. 2024 08h42 HE
|
OXB
Press release OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024 Delivering Pure-Play CDMO Growth Strategy Continued execution of "One OXB" strategy with global integration...
Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO
18 sept. 2024 07h00 HE
|
OXB
Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO Oxford, UK – 18 September 2024: OXB (LSE:OXB), a quality and innovation-led cell and gene...
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today
02 sept. 2024 07h00 HE
|
Oxford BioMedica plc
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today Oxford, UK – 2 September 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, "OXB" or “the Company”), a quality and...
Oxford Biomedica to host a free webinar showcasing its AAV expertise
27 août 2024 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica to host a free webinar showcasing its AAV expertise Oxford, UK - 27 August 2024: On Wednesday 11 September 2024, Oxford Biomedica, a quality and innovation-led cell and gene therapy...
Oxford Biomedica – Half Year Trading Update and Notice of Interim Results
08 août 2024 07h00 HE
|
Oxford BioMedica plc
Half Year Trading Update and Notice of Interim Results Full year 2024 revenue and medium-term financial guidance reiterated; underpinned by OXB’s growing market share in the expanding cell and gene...